Literature DB >> 16861342

Targeting self-antigens through allogeneic TCR gene transfer.

Moniek A de Witte1, Miriam Coccoris, Monika C Wolkers, Marly D van den Boom, Elly M Mesman, Ji-Ying Song, Martin van der Valk, John B A G Haanen, Ton N M Schumacher.   

Abstract

Adoptive transfer of T-cell receptor (TCR) genes has been proposed as an attractive approach for immunotherapy in cases where the endogenous T-cell repertoire is insufficient. While there are promising data demonstrating the capacity of TCR-modified T cells to react to foreign antigen encounter, the feasibility of targeting tumor-associated self-antigens has not been addressed. Here we demonstrate that T-cell receptor gene transfer allows the induction of defined self-antigen-specific T-cell responses, even when the endogenous T-cell repertoire is nonreactive. Furthermore, we show that adoptive transfer of T-cell receptor genes can be used to induce strong antigen-specific T-cell responsiveness in partially MHC-mismatched hosts without detectable graft versus host disease. These results demonstrate the feasibility of using a collection of "off the shelf" T-cell receptor genes to target defined tumor-associated self-antigens and thereby form a clear incentive to test this immunotherapeutic approach in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861342     DOI: 10.1182/blood-2005-08-009357

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Toll-like receptors in tumor immunotherapy.

Authors:  Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas C Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

2.  Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Authors:  Raquel Gomez-Eerland; Bastiaan Nuijen; Bianca Heemskerk; Nienke van Rooij; Joost H van den Berg; Jos H Beijnen; Wolfgang Uckert; Pia Kvistborg; Ton N Schumacher; John B A G Haanen; Annelies Jorritsma
Journal:  Hum Gene Ther Methods       Date:  2014-09-22       Impact factor: 2.396

Review 3.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

4.  Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.

Authors:  Laura A Johnson; Bianca Heemskerk; Daniel J Powell; Cyrille J Cohen; Richard A Morgan; Mark E Dudley; Paul F Robbins; Steven A Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer.

Authors:  Mario Bunse; Gavin M Bendle; Carsten Linnemann; Laura Bies; Stephan Schulz; Ton N Schumacher; Wolfgang Uckert
Journal:  Mol Ther       Date:  2014-07-22       Impact factor: 11.454

6.  TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer.

Authors:  Hongwei Shao; Wenfeng Zhang; Qinglian Hu; Fenglin Wu; Han Shen; Shulin Huang
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

7.  Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease.

Authors:  Gerald P Morris; Geoffrey L Uy; David Donermeyer; John F Dipersio; Paul M Allen
Journal:  Sci Transl Med       Date:  2013-06-05       Impact factor: 17.956

Review 8.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes.

Authors:  Adam M Farkas; Douglas M Marvel; Olivera J Finn
Journal:  J Immunol       Date:  2013-02-18       Impact factor: 5.422

10.  TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

Authors:  Moniek A de Witte; Gavin M Bendle; Marly D van den Boom; Miriam Coccoris; Todd D Schell; Satvir S Tevethia; Harm van Tinteren; Elly M Mesman; Ji-Ying Song; Ton N M Schumacher
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.